Amivantamab-based regimens have a role both in the upfront setting and, especially, in the relapsed/refractory setting after prior TKI failure in patients with EGFR-mutant NSCLC [40,41]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.